Results 51 to 60 of about 294,536 (285)

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. [PDF]

PLoS Pathogens, 2013
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine.
Constantinos Kurt Wibmer, Jinal N Bhiman, Elin S Gray, Nancy Tumba, Salim S Abdool Karim, Carolyn Williamson, Lynn Morris, Penny L Moore   +7 more
doaj   +1 more source

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection [PDF]

Current Opinion in HIV and AIDS, 2014
Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins.
Cynthia A, Derdeyn, Penny L, Moore, Lynn, Morris   +2 more
openaire   +2 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs)

Virology Journal, 2012
Despite enormous difficulties to induce antibodies neutralizing HIV-1, especially broadly neutralizing antibodies directed against the conserved membrane proximal external region (MPER) of the transmembrane envelope protein, such antibodies can be easily
Denner Joachim, Mihica Debora, Kaulitz Danny, Schmidt Christa-Maria   +3 more
doaj   +1 more source

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge [PDF]

, 2016
End-stage liver disease caused by hepatitis C virus (HCV) infection is a major indication for liver transplantation. However, immediately after transplantation the liver graft of viremic patients universally becomes infected by circulating virus ...
Baumert, Thomas F., Cole, Sarah, Desombere, Isabelle, Fafi-Kremer, Samira, Farhoudi, Ali, Heydmann, Laura, Leroux-Roels, Geert, McKeating, Jane A., Meuleman, Philip, Patel, Arvind H., Pessaux, Patrick, Van Houtte, Freya, Verhoye, Lieven   +12 more
core   +3 more sources

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies

Frontiers in Microbiology, 2021
The rapid spread of SARS-CoV-2 has caused the COVID-19 pandemic, resulting in the collapse of medical care systems and economic depression worldwide. To combat COVID-19, neutralizing antibodies have been investigated and developed.
Keng-Chang Tsai, Keng-Chang Tsai, Yu-Ching Lee, Yu-Ching Lee, Yu-Ching Lee, Yu-Ching Lee, Yu-Ching Lee, Tien-Sheng Tseng   +7 more
doaj   +1 more source

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. [PDF]

, 2019
Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal models, suggesting that a vaccine that elicits these antibodies would be protective in humans.
Abernathy, Morgan E, Barnes, Christopher O, Bauer, Jens, Bjorkman, Pamela J, Cohen, Alexander A, Escolano, Amelia, Gao, Han, Gautam, Rajeev, Gazumyan, Anna, Golijanin, Jovana, Gristick, Harry B, Irvine, Darrell J, Keeffe, Jennifer R, Martin, Malcolm A, McGuire, Andrew T, Merkenschlager, Julia, Montefiori, David C, Nogueira, Lilian, Nussenzweig, Michel C, Oliveira, Thiago Y, Pai, Joy, Seaman, Michael S, Silva, Murillo, Stamatatos, Leonidas, Voll, Alisa V, Wang, Haoqing, Wang, Zijun, Wells, Lance, West, Anthony P, Yao, Kai-Hui, Yost, Daniel, Zhao, Peng   +31 more
core  

Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift [PDF]

, 1997
Ten antisera were produced in rabbits by two or three intravenous injections of inactivated whole influenza type A virions. All contained haemagglutination-inhibition (HI) antibody directed predominantly to an epitope in antigenic site B and, in addition,
Cleveland, S. Matthew, Dimmock, N. J., Taylor, H. P.   +2 more
core   +2 more sources

NEUTRALIZING ANTIBODIES IN ABORTIVE POLIOMYELITIS [PDF]

Journal of Experimental Medicine, 1933
The neutralizing antibody content for poliomyelitis virus has been tested with both a human and a passage strain of the virus in serial samples of sera from five mild cases of abortive poliomyelitis, and an increase in this antibody content has been demonstrated in convalescent samples obtained within 4 weeks of the acute illness.
J D, Trask, J R, Paul
openaire   +2 more sources